Pasithea Therapeutics Corp. — Director's Dealing 2022

Jun 27, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2022-06-27

Reporting Person: STEINMAN LAWRENCE (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-27	Common Stock	A	5000	$1	Acquired	1262174	Direct